Company Description
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas.
The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease.
The company was founded in 2014 and is based in London, the United Kingdom.
| Country | United Kingdom |
| Founded | 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 904 |
| CEO | Matthew Gline |
Contact Details
Address: Clarendon House, 2 Church Street Hamilton Hm11, D0 HM11 Bermuda | |
| Phone | 441-295-5950 |
| Website | roivant.com |
Stock Details
| Ticker Symbol | ROIV |
| Exchange | NASDAQ |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| CIK Code | 0001635088 |
| CUSIP Number | G76279101 |
| ISIN Number | BMG762791017 |
| Employer ID | 98-1173944 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Matthew Gline | Chief Executive Officer and Director |
| Dr. Eric Venker M.D., Pharm.D. | President and Chief Operating Officer |
| Dr. Mayukh Sukhatme M.D. | President, Chief Investment Officer and Director |
| Richard Pulik | Chief Financial Officer |
| Rakhi Kumar | Chief Accounting Officer |
| Dr. Huafeng Xu Ph.D. | Chief Technology Officer |
| Jo Chen | General Counsel |
| Kelly Graff | Head of People |
| Marianne L. Romeo | Head of Global Transactions and Risk Management |
| Alex Gasner | Executive Vice President of Roivant Health |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 2, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Apr 2, 2024 | 8-K | Current Report |
| Mar 7, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 13, 2024 | 10-Q | Quarterly Report |